RT Journal Article
SR Electronic
T1 The Feasibility of Studying Metabolites in PICU Multi-Organ Dysfunction Syndrome Patients Over an 8-day Course Using An Untargeted Approach
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.04.20244053
DO 10.1101/2020.12.04.20244053
A1 Mara L. Leimanis-Laurens
A1 Danny Gil
A1 Andrew Kampfshulte
A1 Claire Krohn
A1 Elizabeth Prentice
A1 Dominic Sanfilippo
A1 Jeremy W. Prokop
A1 Todd Lydic
A1 Surender Rajasekaran
YR 2020
UL http://medrxiv.org/content/early/2020/12/07/2020.12.04.20244053.abstract
AB Metabolites are generated from critical biological functions and metabolism. This pediatric study reviewed plasma metabolites in patients suffering from multi-organ dysfunction syndrome (MODS) in the pediatric intensive care unit (PICU) using an untargeted metabolomics approach. Patients meeting criteria for MODS were screened for eligibility and consented (n=24), and blood samples were collected at baseline, 72 hours, and 8 days; control patients (n=4), were presenting for routine sedation in an outpatient setting. A sub-set of MODS patients (n=8) required additional support with veno-atrial extracorporeal membrane oxygenation (VA-ECMO) therapy. Metabolites from thawed blood plasma were determined from ion pairing reversed-phase LC-MS analysis. Chromatographic peak alignment, identification, relative quantitation, statistical and bioinformatics evaluation were performed using MAVEN and MetaboAnalyst 4.0. Metabolite analysis revealed 115 peaks per sample. From the PLS-DA with VIP scores above ≥2.0, 7 dynamic metabolites emerged over the 3 time points: tauro-chenodeoxycholic acid (TCDCA), hexose, p-hydroxybenzoate, hydroxyphenylacetic acid (HPLA), 2_3-dihydroxybenzoic acid, 2-keto-isovalerate, and deoxyribose phosphate. After Bonferonni adjustment for repeated measures hexose and p-hydroxybenzoate were significant at one time point, or more. Kendall’s tau-b test was used for internal validation of creatinine. Metabolites may be benign or significant in describing a patient’s pathophysiology and require operator interpretation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSpectrum Health Office of Research (SHOR) funding initiative for precision medicine (R51100431217) Helen DeVos Childrens Hospital Foundation (HDVCH) grant (R51100881018) and HDVCH Foundation grant (DG SR ML). NIH Office of the Director and NIEHS grant K01ES025435 (JWP).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Spectrum Health IRB 2016-062-SH/HDVCH.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is available upon request.HPLAhyroxyphenylacetic acidLC-MSLiquid chromatography-mass spectrometryMODSmulti-organ dysfunction syndromePICUpediatric intensive care unitPLS-DApartial least squares-discriminant analysisVA-ECMOveno-atrial extracorporeal membrane oxygenationVIPvariance of importanceTCDCAtauro-chenodeoxycholic acid.